Archive | 2018 Rayno Biopharmaceuticals Portfolio

The Rayno Biopharmaceuticals Portfolio up to date picks for 2017 are below.  We have recovered from the bear market for biotechnology stocks since the 2015 “bubble” peak of July 17, 2015. The sector bottomed on November 3, 2016 with IBB at  $246 and is up 19% YTD.

BIO Investor Forum: Oct 26,27

We attended the BIO Investor Forum in San Francisco last week and here is my brief summary of funding, important trends and technologies. Investor Uprising – Rod Raynovich – Biotech Bull Market Intact, Despite Funding Gap

Continue Reading 0

Rayno Life Science Portfolio Winners: BMRN,GILD,QQQ, VPHM

We attended the BIO Investor Forumin San Francisco this week and will provide a brief review of select technologies and companies on Monday. Despite a funding gap for earlier stage companies we believe the life science sector continues to offer good opportunities for investors. By now you have read every market summary on the big […]

Continue Reading 0

Healthcare and Biotech for Relative Safety: ALXN,REGN,OPTR,SGEN

A Place to Hide from Volatility Today was not as bad as early futures and European markets would portend. The S&P cut its losses to 0.74% and the NASDAQ was down only 0.26%. But as we recommended last month the healthcare sector looks good for relative safety. Drug stocks that pay dividends and large cap […]

Continue Reading 0

Rayno Life Science Portfolio 2011 H1 Update-Biopharm Big Winners:BIIB, CBST, REGN, SGEN

2011 A Huge Year for Life Science Investing As of mid-year the Rayno Life Science Biopharmaceutical Portfolio was up over 20% beating most  ETF’s and Life Science mutual funds. Our two recommended biotech ETF’s for balancing and overweighting were FBT up 13.3% and IBB up 15.3%. Returns could have been much higher with rebalancing strategies […]

Continue Reading 0

Rayno Biopharma Portfolio: Update 4/11,6/11, and 11/11,21/11

11/18 Added Dendreon (DNDN) at $8.00 level.IBB is preferred biotech ETF. 11/15/11 Comments: Under review: ImmunoGen (IMGN) Dropped FBT an ETF in favor of  IBB or possibly XBI. For bullish equity allocation in Tech and Biotech use QQQ. 6/20/11 NASDAQ (2632) Market stabilizing after 7% correction.QQQ down <1%. IBB up 10% YTD. Mid-cap biopharms are up […]

Continue Reading 0